1. Membrane Transporter/Ion Channel
  2. SGLT

Empagliflozin (Synonyms: BI 10773)

Cat. No.: HY-15409 Purity: 99.91% ee.: 98.83%
Data Sheet SDS Handling Instructions

Empagliflozin is a selective sodium glucose cotransporter-2 (SGLT-2) inhibitor with an IC50 of 3.1 nM for hSGLT-2.

For research use only. We do not sell to patients.
Empagliflozin Chemical Structure

Empagliflozin Chemical Structure

CAS No. : 864070-44-0

Size Price Stock Quantity
Free Sample (0.5-1 mg)   Apply now  
10 mM * 1 mL in DMSO $55 In-stock
5 mg $50 In-stock
10 mg $70 In-stock
50 mg $170 In-stock
100 mg $270 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

    Empagliflozin purchased from MCE. Usage Cited in: JACC Basic Transl Sci. 2017 Aug;2(3):347-354.

    Improved In Vivo Cardiac Function in Empagliflozin-Treated Mice With Heart Failure Is PreservedEx Vivo. Hearts from vehicle- and Empa-treated mice with HF are perfused ex vivo to measure cardiac function. Cardiac output (A) and cardiac work (B) are measured using ex vivo perfused working hearts.

    Featured Recommendations

    Related Screening Libraries:

    • Biological Activity

    • Protocol

    • Technical Information

    • Purity & Documentation

    • References

    Description

    Empagliflozin is a selective sodium glucose cotransporter-2 (SGLT-2) inhibitor with an IC50 of 3.1 nM for hSGLT-2.

    IC50 & Target

    IC50: 3.1 nM (SGLT-2), 1.1 μM (SGLT-5), 2 μM (SGLT-6), 8.3 μM (SGLT-1), 11 μM (SGLT-4)[1]

    In Vitro

    Empagliflozin is a potent and competitive SGLT-2 inhibitor with an excellent selectivity profile and the highest selectivity window of the tested SGLT-2 inhibitors over hSGLT-1. Empagliflozin inhibits the uptake of [14C]-alpha-methyl glucopyranoside (AMG) via hSGLT-2 in a dose-dependent manner with an IC50 of 3.1 nM, but is less potent for other SGLTs (IC50 range: 1100-11000 nM). [3H]-Empagliflozin displays a high affinity for SGLT-2 with a mean Kd of 57±37 nM in the absence of glucose in kinetic binding experiments[1].

    In Vivo

    Glucose intolerance is significantly improved after 8 days of Empagliflozin treatment at either dose (3mg/kg Empagliflozin 3058±180 vs 10mg/kg Empagliflozin 3090±219). Therefore, acute treatment with Empagliflozin has a beneficial effect on hyperglycemia and glucose intolerance. Since there are no significant differences in blood glucose homeostasis with the two different doses of Empagliflozin, and random blood glucose levels of T1DM mice are significantly improved by 3mg/kg of Empagliflozin, the effect of the lower dose of Empagliflozin (3mg/kg) is investigated on preserving β-cell mass and function[2].

    Clinical Trial
    NCT Number Sponsor Condition Start Date Phase
    NCT01248364 Boehringer Ingelheim Diabetes Mellitus, Type 2 November 2010 Phase 2
    NCT01111318 Boehringer Ingelheim Hepatic Insufficiency|Healthy July 2010 Phase 1
    NCT01392560 Boehringer Ingelheim Diabetes Mellitus, Type 1 June 2011 Phase 2
    NCT02172209 Boehringer Ingelheim Healthy January 2008 Phase 1
    NCT01301742 Boehringer Ingelheim Healthy February 2011 Phase 1
    NCT02172261 Boehringer Ingelheim Healthy April 2009 Phase 1
    NCT01111331 Boehringer Ingelheim Healthy May 2010 Phase 1
    NCT01011868 Boehringer Ingelheim|Eli Lilly and Company Diabetes Mellitus, Type 2 November 2009 Phase 2
    NCT01306175 Boehringer Ingelheim Healthy February 2011 Phase 1
    NCT01189201 Boehringer Ingelheim Healthy August 2010 Phase 1
    NCT02172248 Boehringer Ingelheim Healthy January 2009 Phase 1
    NCT01242176 Boehringer Ingelheim Healthy November 2010 Phase 1
    NCT02172196 Boehringer Ingelheim Healthy May 2009 Phase 1
    NCT02276365 Boehringer Ingelheim Healthy June 2009 Phase 1
    NCT01131676 Boehringer Ingelheim|Eli Lilly and Company Diabetes Mellitus, Type 2 July 2010 Phase 3
    NCT02172222 Boehringer Ingelheim Healthy July 2009 Phase 1
    NCT01167881 Boehringer Ingelheim|Eli Lilly and Company Diabetes Mellitus, Type 2 August 2010 Phase 3
    NCT01368081 Boehringer Ingelheim|Eli Lilly and Company Diabetes Mellitus, Type 2 May 2011 Phase 3
    NCT02182453 Boehringer Ingelheim Healthy June 2008 Phase 1
    NCT01370005 Boehringer Ingelheim|Eli Lilly and Company Diabetes Mellitus, Type 2|Hypertension June 2011 Phase 3
    NCT01306214 Boehringer Ingelheim|Eli Lilly and Company Diabetes Mellitus, Type 2|Obesity February 2011 Phase 3
    NCT01164501 Boehringer Ingelheim|Eli Lilly and Company Diabetes Mellitus, Type 2|Renal Insufficiency July 2010 Phase 3
    NCT02172170 Boehringer Ingelheim Healthy January 2007 Phase 1
    NCT01276301 Boehringer Ingelheim Healthy January 2011 Phase 1
    NCT01210001 Boehringer Ingelheim|Eli Lilly and Company Diabetes Mellitus, Type 2 September 2010 Phase 3
    NCT00881530 Boehringer Ingelheim Diabetes Mellitus, Type 2 March 2009 Phase 2
    NCT02172274 Boehringer Ingelheim Healthy June 2008 Phase 1
    NCT00558571 Boehringer Ingelheim Diabetes Mellitus, Type 2 January 2008 Phase 1
    NCT01211197 Boehringer Ingelheim Diabetes Mellitus, Type 2 October 2010 Phase 1
    NCT01304329 Boehringer Ingelheim Healthy February 2011 Phase 1
    NCT01159600 Boehringer Ingelheim|Eli Lilly and Company Diabetes Mellitus, Type 2 July 2010 Phase 3
    NCT01284621 Boehringer Ingelheim Healthy January 2011 Phase 1
    NCT01193218 Boehringer Ingelheim|Eli Lilly and Company Diabetes Mellitus, Type 2 September 2010 Phase 2
    NCT00885118 Boehringer Ingelheim Diabetes Mellitus, Type 2 April 2009 Phase 2
    NCT01177813 Boehringer Ingelheim|Eli Lilly and Company Diabetes Mellitus, Type 2 July 2010 Phase 3
    NCT01195675 Boehringer Ingelheim Healthy August 2010 Phase 1
    NCT01907113 Boehringer Ingelheim Diabetes Mellitus, Type 2 July 2009 Phase 1
    NCT01328184 Boehringer Ingelheim Healthy April 2011 Phase 1
    NCT00749190 Boehringer Ingelheim Diabetes Mellitus, Type 2 August 2008 Phase 2
    NCT01924767 Boehringer Ingelheim Diabetes Mellitus, Type 2 July 2007 Phase 1
    NCT00789035 Boehringer Ingelheim Diabetes Mellitus, Type 2 October 2008 Phase 2
    NCT02172235 Boehringer Ingelheim Healthy April 2010 Phase 1
    NCT01422876 Boehringer Ingelheim|Eli Lilly and Company Diabetes Mellitus, Type 2 August 2011 Phase 3
    NCT01289990 Boehringer Ingelheim|Eli Lilly and Company Diabetes Mellitus, Type 2 February 2011 Phase 3
    NCT01257334 Taipei Medical University WanFang Hospital Type 2 Diabetes September 2010 Phase 3
    NCT01634100 Boehringer Ingelheim Healthy June 2012 Phase 1
    NCT01867307 Boehringer Ingelheim|Eli Lilly and Company Diabetes Mellitus, Type 2|Healthy June 2013 Phase 2
    NCT01276288 Boehringer Ingelheim Diabetes Mellitus, Type 2 January 2011 Phase 1
    NCT01778049 Boehringer Ingelheim|Eli Lilly and Company Diabetes Mellitus, Type 2 January 2013 Phase 3
    NCT01581658 Boehringer Ingelheim|Eli Lilly and Company Diabetes Mellitus, Type 2 April 2012 Phase 1
    NCT01316341 Boehringer Ingelheim Diabetes Mellitus, Type 2 March 2011 Phase 1
    NCT01248364 Boehringer Ingelheim Diabetes Mellitus, Type 2 November 2010 Phase 2
    NCT01111318 Boehringer Ingelheim Hepatic Insufficiency|Healthy July 2010 Phase 1
    NCT01392560 Boehringer Ingelheim Diabetes Mellitus, Type 1 June 2011 Phase 2
    NCT02172209 Boehringer Ingelheim Healthy January 2008 Phase 1
    NCT01301742 Boehringer Ingelheim Healthy February 2011 Phase 1
    NCT02172261 Boehringer Ingelheim Healthy April 2009 Phase 1
    NCT01111331 Boehringer Ingelheim Healthy May 2010 Phase 1
    NCT01011868 Boehringer Ingelheim|Eli Lilly and Company Diabetes Mellitus, Type 2 November 2009 Phase 2
    NCT01306175 Boehringer Ingelheim Healthy February 2011 Phase 1
    NCT01189201 Boehringer Ingelheim Healthy August 2010 Phase 1
    NCT02172248 Boehringer Ingelheim Healthy January 2009 Phase 1
    NCT01242176 Boehringer Ingelheim Healthy November 2010 Phase 1
    NCT02172196 Boehringer Ingelheim Healthy May 2009 Phase 1
    NCT02276365 Boehringer Ingelheim Healthy June 2009 Phase 1
    NCT01131676 Boehringer Ingelheim|Eli Lilly and Company Diabetes Mellitus, Type 2 July 2010 Phase 3
    NCT02172222 Boehringer Ingelheim Healthy July 2009 Phase 1
    NCT01167881 Boehringer Ingelheim|Eli Lilly and Company Diabetes Mellitus, Type 2 August 2010 Phase 3
    NCT01368081 Boehringer Ingelheim|Eli Lilly and Company Diabetes Mellitus, Type 2 May 2011 Phase 3
    NCT02182453 Boehringer Ingelheim Healthy June 2008 Phase 1
    NCT01370005 Boehringer Ingelheim|Eli Lilly and Company Diabetes Mellitus, Type 2|Hypertension June 2011 Phase 3
    NCT01306214 Boehringer Ingelheim|Eli Lilly and Company Diabetes Mellitus, Type 2|Obesity February 2011 Phase 3
    NCT01164501 Boehringer Ingelheim|Eli Lilly and Company Diabetes Mellitus, Type 2|Renal Insufficiency July 2010 Phase 3
    NCT02172170 Boehringer Ingelheim Healthy January 2007 Phase 1
    NCT01276301 Boehringer Ingelheim Healthy January 2011 Phase 1
    NCT01210001 Boehringer Ingelheim|Eli Lilly and Company Diabetes Mellitus, Type 2 September 2010 Phase 3
    NCT00881530 Boehringer Ingelheim Diabetes Mellitus, Type 2 March 2009 Phase 2
    NCT02172274 Boehringer Ingelheim Healthy June 2008 Phase 1
    NCT00558571 Boehringer Ingelheim Diabetes Mellitus, Type 2 January 2008 Phase 1
    NCT01211197 Boehringer Ingelheim Diabetes Mellitus, Type 2 October 2010 Phase 1
    NCT01304329 Boehringer Ingelheim Healthy February 2011 Phase 1
    NCT01159600 Boehringer Ingelheim|Eli Lilly and Company Diabetes Mellitus, Type 2 July 2010 Phase 3
    NCT01284621 Boehringer Ingelheim Healthy January 2011 Phase 1
    NCT01193218 Boehringer Ingelheim|Eli Lilly and Company Diabetes Mellitus, Type 2 September 2010 Phase 2
    NCT00885118 Boehringer Ingelheim Diabetes Mellitus, Type 2 April 2009 Phase 2
    NCT01177813 Boehringer Ingelheim|Eli Lilly and Company Diabetes Mellitus, Type 2 July 2010 Phase 3
    NCT01195675 Boehringer Ingelheim Healthy August 2010 Phase 1
    NCT01907113 Boehringer Ingelheim Diabetes Mellitus, Type 2 July 2009 Phase 1
    NCT01328184 Boehringer Ingelheim Healthy April 2011 Phase 1
    NCT00749190 Boehringer Ingelheim Diabetes Mellitus, Type 2 August 2008 Phase 2
    NCT01924767 Boehringer Ingelheim Diabetes Mellitus, Type 2 July 2007 Phase 1
    NCT00789035 Boehringer Ingelheim Diabetes Mellitus, Type 2 October 2008 Phase 2
    NCT02172235 Boehringer Ingelheim Healthy April 2010 Phase 1
    NCT01422876 Boehringer Ingelheim|Eli Lilly and Company Diabetes Mellitus, Type 2 August 2011 Phase 3
    NCT01289990 Boehringer Ingelheim|Eli Lilly and Company Diabetes Mellitus, Type 2 February 2011 Phase 3
    NCT01257334 Taipei Medical University WanFang Hospital Type 2 Diabetes September 2010 Phase 3
    NCT01634100 Boehringer Ingelheim Healthy June 2012 Phase 1
    NCT01867307 Boehringer Ingelheim|Eli Lilly and Company Diabetes Mellitus, Type 2|Healthy June 2013 Phase 2
    NCT01276288 Boehringer Ingelheim Diabetes Mellitus, Type 2 January 2011 Phase 1
    NCT01778049 Boehringer Ingelheim|Eli Lilly and Company Diabetes Mellitus, Type 2 January 2013 Phase 3
    NCT01581658 Boehringer Ingelheim|Eli Lilly and Company Diabetes Mellitus, Type 2 April 2012 Phase 1
    NCT01316341 Boehringer Ingelheim Diabetes Mellitus, Type 2 March 2011 Phase 1
    NCT03030222 Saint Luke's Health System Heart Failure July 5, 2017 Phase 4
    NCT02686476 Medanta, The Medicity, India Non Alcoholic Fatty Liver Disease March 2016
    NCT03113110 Medical University of Vienna Posttransplant Diabetes Mellitus January 15, 2017 Phase 2
    NCT02471963 University of Erlangen-Nürnberg Medical School Diabetes Mellitus Type 2 December 2014 Phase 3
    NCT03093103 Centre Hospitalier Universitaire Vaudois Nephropathy March 1, 2017 Phase 2
    NCT02932436 Johannes Gutenberg University Mainz|Boehringer Ingelheim Diabetes Mellitus, Type 2|Diastolic Dysfunction October 2016 Phase 4
    NCT02752113 Institut für Pharmakologie und Präventive Medizin|University of Erlangen-Nürnberg Medical School Diabetes Mellitus Type 2 April 2016 Phase 3
    NCT03059056 British University In Egypt Diabetes Mellitus February 2, 2017 Phase 1
    NCT03008551 University of Hull Polycystic Ovary Syndrome August 2017 Phase 2|Phase 3
    NCT02998970 St. Michael's Hospital, Toronto|Boehringer Ingelheim (Canada) LTD Diabetes|Cardiovascular Disease January 2017 Phase 4
    NCT02401880 Profil Institut für Stoffwechselforschung GmbH Type 2 Diabetes Mellitus May 2015 Phase 4
    NCT03087773 Medical University of Graz|United Arab Emirates University|Medical University of Vienna|Landeskrankenhaus Feldkirch|Krankenhaus der Barmherzigen Brüder Linz|Kepler University Hospital|Paracelsus Medical University Acute Myocardial Infarction May 11, 2017 Phase 3
    NCT03157414 Oslo University Hospital Diabetes Mellitus|Renal Insufficiency|Safety Issues November 2016 Phase 4
    NCT03132181 RWTH Aachen University|Boehringer Ingelheim Diabetes Mellitus Type 2 (T2DM) April 24, 2017 Phase 2
    NCT02637973 The Deutsche Diabetes Forschungsgesellschaft e.V.|Boehringer Ingelheim|German Diabetes Center Type 2 Diabetes|Non-alcoholic Fatty Liver Disease December 2015 Phase 4
    NCT02632747 Boehringer Ingelheim|Eli Lilly and Company Diabetes Mellitus, Type 1 May 10, 2016 Phase 2
    NCT03078101 Medical University of Vienna|Attoquant Diagnostics Diabetic Kidney Disease|Diabetes Mellitus, Type 2|Chronic Kidney Disease stage3|Chronic Kidney Disease stage4 March 2017 Phase 2
    NCT02964715 University of Malaya Type2 Diabetes|NAFLD November 2016 Phase 4
    NCT02815644 Boehringer Ingelheim Healthy July 2016 Phase 1
    NCT02577315 Boehringer Ingelheim Healthy September 2015 Phase 1
    NCT03227484 University Hospital Tuebingen PreDiabetes|Body Weight June 1, 2017 Phase 2
    NCT03027960 Yale University|Boehringer Ingelheim Heart Failure|Type II; Diabetes June 27, 2017 Phase 2
    NCT01001962 Aristotle University Of Thessaloniki Hypertension|Type II Diabetes January 2016 Phase 4
    NCT02230995 Boehringer Ingelheim|Eli Lilly and Company Healthy September 2014 Phase 1
    NCT02266472 Boehringer Ingelheim|Eli Lilly and Company Healthy November 2014 Phase 1
    NCT03200860 University Medical Center Groningen Heart Failure Acute|Heart Failure,Congestive|Heart Failure; With Decompensation December 2017 Phase 2
    NCT03215069 Mount Sinai Hospital, Canada|Boehringer Ingelheim Gestational Diabetes September 1, 2017 Phase 3
    NCT03208465 CHEOL WHAN LEE, M.D., Ph.D|Asan Medical Center Diabetes Mellitus|Coronary Disease August 15, 2017 Phase 4
    NCT03202667 University Hospital, Basel, Switzerland SIAD - Syndrome of Inappropriate Antidiuresis|Hyponatremia August 2017 Phase 2|Phase 3
    NCT02758171 Boehringer Ingelheim|Eli Lilly and Company Healthy May 2016 Phase 1
    NCT02854748 Chong Kun Dang Pharmaceutical Diabetes Mellitus, Type II August 2016 Phase 1
    NCT02890745 Henrik Enghusen Poulsen|University Hospital, Gentofte, Copenhagen|University of Copenhagen|Rigshospitalet, Denmark Diabetes Mellitus, Type 2 November 2016 Phase 2
    NCT02798744 University of Leicester|Loughborough University|University Hospitals, Leicester Diabetes Mellitus, Type 2 September 2016 Phase 4
    NCT01969747 Boehringer Ingelheim|Eli Lilly and Company Diabetes Mellitus, Type 1 November 2013 Phase 2
    NCT02728453 Hannover Medical School|Hannover Clinical Trial Center GmbH|Boehringer Ingelheim Diabetes Mellitus Type 2 May 2016 Phase 4
    NCT02874807 University Hospital, Basel, Switzerland SIADH August 2016 Phase 2|Phase 3
    NCT02102932 Boehringer Ingelheim|Eli Lilly and Company Healthy May 2014 Phase 1
    NCT03128528 University of Erlangen-Nürnberg Medical School Chronic Heart Failure July 1, 2017 Phase 2
    NCT02121483 Boehringer Ingelheim|Eli Lilly and Company Diabetes Mellitus, Type 2 June 2014 Phase 1
    NCT02414958 Boehringer Ingelheim|Eli Lilly and Company Diabetes Mellitus, Type 1 June 30, 2015 Phase 3
    NCT02589626 Boehringer Ingelheim Diabetes Mellitus, Type 2 October 29, 2015 Phase 4
    NCT01844531 Boehringer Ingelheim Healthy April 2013 Phase 1
    NCT02985242 Hannover Medical School Diabetes Mellitus, Type II December 2016 Phase 4
    NCT01984606 Boehringer Ingelheim|Eli Lilly and Company Diabetes Mellitus, Type 2 January 2015 Phase 3
    NCT02864914 Boehringer Ingelheim|Eli Lilly and Company Diabetes Mellitus, Type 2 March 15, 2016
    NCT02782624 Boehringer Ingelheim Healthy September 2009 Phase 1
    NCT01451775 Boehringer Ingelheim Healthy October 2011 Phase 1
    NCT03173963 National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health Clinical Center (CC) Diabetic Kidney Disease|Diabetes Mellitus Type 2 July 28, 2017 Phase 3
    NCT03198585 Morten Schou|Herlev and Gentofte Hospital Heart Failure With Reduced Ejection Fraction June 29, 2017 Phase 2
    NCT03152552 Novartis Pharmaceuticals|Novartis Diabetes Type 2 With Heart Failure July 26, 2017 Phase 2
    NCT03226457 University of Dundee|British Heart Foundation Heart Failure|Type 2 Diabetes Mellitus August 2017 Phase 4
    NCT03057977 Boehringer Ingelheim|Eli Lilly and Company Heart Failure March 6, 2017 Phase 3
    NCT03057951 Boehringer Ingelheim|Eli Lilly and Company Heart Failure March 2, 2017 Phase 3
    NCT02863328 Novo Nordisk A/S Diabetes|Diabetes Mellitus, Type 2 August 10, 2016 Phase 3
    NCT01811953 Boehringer Ingelheim Healthy March 2013 Phase 1
    NCT03200782 University Hospital, Basel, Switzerland Postprandial Hypoglycemia|Bariatric Surgery|Late Dumping Syndrome May 30, 2017
    NCT02453555 Boehringer Ingelheim|Eli Lilly and Company Diabetes Mellitus, Type 2 May 14, 2015 Phase 3
    NCT02580591 Boehringer Ingelheim|Eli Lilly and Company Diabetes Mellitus, Type 1 October 12, 2015 Phase 3
    NCT02489968 Boehringer Ingelheim|Eli Lilly and Company Diabetes Mellitus, Type 2 May 12, 2015 Phase 3
    NCT01947855 Boehringer Ingelheim|Eli Lilly and Company Diabetes Mellitus, Type 2 September 2013 Phase 3
    NCT01975220 Boehringer Ingelheim|Eli Lilly and Company Healthy October 2013 Phase 1
    NCT02729766 University Hospital, Basel, Switzerland Inappropriate ADH Syndrome March 2016 Phase 2|Phase 3
    NCT02106923 Boehringer Ingelheim|Eli Lilly and Company Healthy April 2014 Phase 1
    NCT02589639 Boehringer Ingelheim|Eli Lilly and Company Diabetes Mellitus, Type 2 October 2015 Phase 4
    NCT03151343 Caroline M Kistorp|Danish Heart Foundation|Herlev and Gentofte Hospital|Rigshospitalet, Denmark Type2 Diabetes Mellitus March 29, 2017 Phase 3
    NCT03050229 Jichi Medical University|Boehringer Ingelheim|Eli Lilly and Company Nocturnal Hypertension|T2DM (Type 2 Diabetes Mellitus) January 2017 Phase 4
    NCT01649297 Boehringer Ingelheim|Eli Lilly and Company Diabetes Mellitus, Type 2 October 2012 Phase 2
    NCT02821910 Boehringer Ingelheim|Eli Lilly and Company Healthy July 2016 Phase 1
    NCT01719003 Boehringer Ingelheim|Eli Lilly and Company Diabetes Mellitus, Type 2|Hyperglycemia October 2012 Phase 3
    NCT02028767 Boehringer Ingelheim Healthy January 2014 Phase 1
    NCT03060980 Intarcia Therapeutics Diabetes Mellitus, Type 2 March 3, 2017 Phase 3
    NCT01734785 Boehringer Ingelheim|Eli Lilly and Company Diabetes Mellitus, Type 2 January 2013 Phase 3
    NCT02964572 Yonsei University Type2 Diabetes Mellitus November 2016
    NCT02768220 Northwell Health SGLT-2 Inhibitors|Advanced Glycation End Products|Diabetes December 1, 2017 Phase 4
    NCT01672788 Boehringer Ingelheim Healthy August 2012 Phase 1
    NCT02702011 Boehringer Ingelheim|Eli Lilly and Company Diabetes Mellitus, Type 1 March 2016 Phase 2
    NCT02833415 University of Texas Southwestern Medical Center|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Obesity, Visceral March 2016 Phase 4
    NCT03118336 Assistance Publique Hopitaux De Marseille Type 2 Diabetes June 16, 2017 Phase 3
    NCT02792400 University Hospital, Gentofte, Copenhagen|Eli Lilly and Company Type 2 Diabetes May 2016
    View MoreCollapse
    References
    Preparing Stock Solutions
    Concentration Volume (DMSO) Mass 1 mg 5 mg 10 mg
    1 mM 2.2177 mL 11.0887 mL 22.1774 mL
    5 mM 0.4435 mL 2.2177 mL 4.4355 mL
    10 mM 0.2218 mL 1.1089 mL 2.2177 mL
    Kinase Assay
    [1]

    Membranes (60 μg/well) are assayed in a 10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) buffer (pH 7.4) containing 137 mM NaCl in the presence or absence of 20 mM glucose and indicated concentrations of [3H]-Empagliflozin in 96-well plates at room temperature for 2 h. Incubations are stopped by rapid filtration through GF/B Filterplates impregnated with polyethyleneimine 0.5% and prewetted with 0.9% NaCl solution, and washed four times with 0.9% NaCl solution (4°C) using a Harvester Filtermate 96. Filterplates are dried for 2 h and 50 μL of Microscint 20 is added to each well. Radioactivity retained on the filters is measured using the TopCount NXT. In parallel, the actual amount of activity used in the assays is determined by adding the same amount of [3H]-Empagliflozin that is added per well in the radioligand binding studies and 4 mL Ultima Gold Scintilator into 5 mL vials and measuring using a Tricarb 2900TR. Non-specific [3H]-Empagliflozin-binding is determined in the presence of 30 μM dapagliflozin[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Administration
    [2]

    Empagliflozin is dissolved in hydroxy ethyl cellulose (HEC) (Mice)[2].

    Mice[2]
    Male C57BL/6J mice (10 weeks of age) are used. Empagliflozin is dissolved in hydroxy ethyl cellulose (HEC) and administered to mice in the experimental group (3 or 10 mg/kg) by oral gavage once daily for 8 days, whereas the vehicle group is given same volume of HEC alone. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    References
    Molecular Weight

    450.91

    Formula

    C₂₃H₂₇ClO₇

    CAS No.

    864070-44-0

    Storage

    Please store the product under the recommended conditions in the Certificate of Analysis.

    Shipping

    Room temperature in continental US; may vary elsewhere

    Solvent & Solubility

    10 mM in DMSO

    Empagliflozin is preppared in 0.5% hydroxyethyl cellulose[3].

    * "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

    References

    Purity: 99.91% ee.: 98.83%

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product name

     

    Salutation

    Applicant name *

     

    Email address *

    Phone number

     

    Organization name *

    Country *

     

    Requested quantity *

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Empagliflozin
    Cat. No.:
    HY-15409
    Quantity: